··

··

··

RESEARCH USE ONLY

#саркопенія

Monographs tagged “саркопенія”.

Muscle growthBimagrumab (BYM338): anti-ActRII monoclonal antibody — mechanism, clinical record and limits of the evidenceBimagrumab (BYM338) is a human IgG monoclonal antibody (~150 kDa, not a peptide) that blocks activin type II receptors (ActRIIA/ActRIIB), silencing myostatin, activin A and GDF-11 signalling together. A review of receptor-level blockade, the three Novartis clinical programmes, the recurring mass-without-function result, and the metabolic pivot toward body composition.